Baxter BioScience recently agreed to pay $900 million for the Oncaspar® product portfolio owned the Italian biopharma company, Sigma Tau Financiaria SpA. Oncaspar is a biologic used as part of a multi-agent chemotherapy regimen to treat lymphoblastic leukemia, and is marketed in the United States, Germany, Poland and certain other countries. In addition to the drug, Baxter BioScience also acquired another investigational biologic and an established oncology infrastructure with annual sales of approximately $100 million. Very soon, Baxter International Inc. (NYSE: BAX) plans to spin off Baxter BioScience into a new company called Baxalta Incorporated. This deal is a nice going-away present, for sure.
Baxalta’s Predecessor Readies for the Spin Off
by Lisa Phillips | May 18, 2015 5:55 pm | Biotechnology
Categories
- Ambulatory Surgery Centers
- Behavioral Health Care
- Biotechnology
- CDMO
- CRO
- eHealth
- Healthcare M&A News Leads
- Healthcare Market Updates
- Healthcare Staffing
- Home Health & Hospice
- Hospitals
- Laboratories, MRI & Dialysis
- Long-Term Care
- Managed Care
- Medical Devices
- Medical Office Buildings
- Occupational Health
- Other Services
- Pharmaceuticals
- Physician Medical Groups
- Private Equity
- Rehabilitation
- SPAC
- Specialty Pharmacies
- Uncategorized
- Urgent Care Centers